Dogwood Therapeutics, Inc. Common Stock
DWTXDogwood Therapeutics, Inc. (DWTX) is a biotechnology company focused on developing innovative therapies targeting the central nervous system and ophthalmic conditions. The company leverages its expertise in drug discovery and development to create novel treatments for neurological disorders, with an emphasis on improving patient outcomes through precision medicine approaches.
Company News
DelveInsight released a comprehensive analysis of the chronic and acute pain clinical trial pipeline, identifying 150+ active companies developing 200+ pipeline drugs across various clinical stages. The report highlights a shift toward non-opioid, targeted, and multimodal approaches due to growing concerns about opioid dependence. Recent developm...
The chemotherapy-induced peripheral neuropathy (CIPN) treatment market is expected to grow significantly between 2025-2034, driven by rising cancer incidence, lack of approved therapies, and emerging novel drug treatments.
Dogwood Therapeutics reported ongoing Phase 2b trial for Halneuron®, a potential treatment for chemotherapy-induced neuropathic pain, with 52 patients enrolled and interim data expected in Q4 2025. The company experienced increased research and development expenses and reported a net loss of $3.8 million for Q2 2025.
The sodium channel blocker market is expanding due to the increasing prevalence of neuropathic pain and the rising incidence of cardiac arrhythmias. Over 20 pharmaceutical companies are actively developing 25+ pipeline sodium channel blockers, with promising drugs like Cenobamate, VX-548, and Vormatrigine in different clinical trial phases.
